-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eclitasertib in Rheumatoid Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eclitasertib in Rheumatoid Arthritis Drug Details: DNL-758 (SAR-443122) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details:DNL-788 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INCB-86550 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INCB-86550 in Melanoma Drug Details:INCB-86550 is under development for the treatment of advanced solid tumors including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Alzheimer’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Alzheimer's Disease Drug Details:DNL-788 is under development for the treatment of Alzheimer’s disease, amyotrophic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Primary Progressive Multiple Sclerosis (PPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Primary Progressive Multiple Sclerosis (PPMS) Drug Details:DNL-788 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GD2-SADA in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GD2-SADA in Solid Tumor Drug Details:Monoclonal antibody conjugate is under development for the treatment of GD-2...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eclitasertib in Cutaneous Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eclitasertib in Cutaneous Lupus Erythematosus Drug Details: DNL-758 (SAR-443122) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eclitasertib in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Eclitasertib in Ulcerative Colitis Drug Details:DNL-758 (SAR-443122) is under development for the treatment of peripheral inflammatory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Amyotrophic Lateral Sclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Amyotrophic Lateral Sclerosis Drug Details:DNL-788 is under development for the treatment of Alzheimer’s disease,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.DNL-788 in Secondary Progressive Multiple Sclerosis (SPMS) Drug Details:DNL-788 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Pancreatic Ductal AdenocarcinomaDrug Details: GRANITE-001 (Zvexneo) is under development for the treatment of pancreatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CLN-619 in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CLN-619 in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: CLN-619 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Sickle Cell Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Briquilimab in Sickle Cell Disease Drug Details:Briquilimab (AMG-191) is under development for the treatment of fanconi...
-
Product Insights
![]()
Denali Com Ppty/ Epic Games/ Turnbridge Equities – Carolina Yard Mixed-Use Development – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Denali Com Ppty/ Epic Games/ Turnbridge Equities - Carolina Yard Mixed-Use Development - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ecubectedin in Dedifferentiated Liposarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ecubectedin in Dedifferentiated Liposarcoma Drug Details: Ecubectedin (PM-14) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-266 in Trigeminal Neuralgia (Tic Douloureux)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ST-266 in Trigeminal Neuralgia (Tic Douloureux) Drug Details: ST-266 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rigosertib Sodium in Epidermolysis Bullosa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rigosertib Sodium in Epidermolysis Bullosa Drug Details: Rigosertib (Estybon, ON 01910.Na and SyB L-1101) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eravacycline Dihydrochloride in Ventilator Associated Pneumonia (VAP)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eravacycline Dihydrochloride in Ventilator Associated Pneumonia (VAP) Drug Details: Eravacycline dihydrochloride (Xerava) is a tetracycline...
-
Product Insights
![]()
Hines Interests/ LC Fulenwider – Denali Logistics Park – Colorado
Equip yourself with the essential tools needed to make informed and profitable decisions with our Hines Interests/ LC Fulenwider - Denali Logistics Park - Colorado report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? ·Unleash the full story:...
-
Company Profile
![]()
Denali Therapeutics Inc – Company Profile
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. Its proprietary drug delivery platform technologies include an antibody transport vehicle and an enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other...
Add to Basket
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.